Affymax, Inc. (AFFY)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2013 | -15.04 Million USD | 83.65% |
| 2012 | -92.03 Million USD | -49.89% |
| 2011 | -61.4 Million USD | -325.01% |
| 2010 | -14.44 Million USD | 81.7% |
| 2009 | -78.94 Million USD | 11.03% |
| 2008 | -88.73 Million USD | -80.58% |
| 2007 | -49.13 Million USD | 8.51% |
| 2006 | -53.71 Million USD | -57.93% |
| 2005 | -34 Million USD | -53.76% |
| 2004 | -22.11 Million USD | -9930.22% |
| 2003 | 225 Thousand USD | 100.79% |
| 2002 | -28.34 Million USD | -163.8% |
| 2001 | -10.74 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2014 Q1 | -1.39 Million USD | 2.59% |
| 2014 Q2 | -953 Thousand USD | 31.54% |
| 2013 Q2 | 14.27 Million USD | 154.48% |
| 2013 Q3 | -1.69 Million USD | -111.86% |
| 2013 Q4 | -1.42 Million USD | 15.54% |
| 2013 Q1 | -26.19 Million USD | 61.58% |
| 2013 FY | -15.04 Million USD | 83.65% |
| 2012 FY | -92.03 Million USD | -49.89% |
| 2012 Q4 | -68.18 Million USD | -184.24% |
| 2012 Q3 | -23.99 Million USD | 23.55% |
| 2012 Q2 | -31.38 Million USD | -199.56% |
| 2012 Q1 | 31.52 Million USD | 207.15% |
| 2011 Q4 | -29.41 Million USD | -199.38% |
| 2011 FY | -61.4 Million USD | -325.01% |
| 2011 Q2 | -12.53 Million USD | -30.1% |
| 2011 Q3 | -9.82 Million USD | 21.59% |
| 2011 Q1 | -9.63 Million USD | 17.97% |
| 2010 Q2 | 17.26 Million USD | 319.6% |
| 2010 FY | -14.44 Million USD | 81.7% |
| 2010 Q4 | -11.74 Million USD | 3.03% |
| 2010 Q3 | -12.1 Million USD | -170.14% |
| 2010 Q1 | -7.86 Million USD | 49.78% |
| 2009 Q2 | -22.54 Million USD | -2.42% |
| 2009 FY | -78.94 Million USD | 11.03% |
| 2009 Q4 | -15.65 Million USD | 16.44% |
| 2009 Q3 | -18.73 Million USD | 16.9% |
| 2009 Q1 | -22.01 Million USD | 16.91% |
| 2008 Q3 | -26.44 Million USD | -34.84% |
| 2008 Q2 | -19.6 Million USD | -21.12% |
| 2008 Q4 | -26.49 Million USD | -0.2% |
| 2008 FY | -88.73 Million USD | -80.58% |
| 2008 Q1 | -16.19 Million USD | -14.55% |
| 2007 Q4 | -14.13 Million USD | -1.81% |
| 2007 Q2 | -11.25 Million USD | -14.09% |
| 2007 Q1 | -9.86 Million USD | -60.95% |
| 2007 FY | -49.13 Million USD | 8.51% |
| 2007 Q3 | -13.88 Million USD | -23.33% |
| 2006 Q4 | -6.13 Million USD | -2.03% |
| 2006 Q3 | -6 Million USD | 80.46% |
| 2006 FY | -53.71 Million USD | -57.93% |
| 2006 Q2 | -30.74 Million USD | -183.9% |
| 2006 Q1 | -10.82 Million USD | 68.22% |
| 2005 Q3 | 22 Thousand USD | 0.0% |
| 2005 Q1 | 22 Thousand USD | 100.1% |
| 2005 Q4 | -34.07 Million USD | -154990.91% |
| 2005 FY | -34 Million USD | -53.76% |
| 2005 Q2 | 22 Thousand USD | 0.0% |
| 2004 Q2 | 38 Thousand USD | 0.0% |
| 2004 Q1 | 38 Thousand USD | 0.0% |
| 2004 FY | -22.11 Million USD | -9930.22% |
| 2004 Q4 | -22.23 Million USD | -58602.63% |
| 2004 Q3 | 38 Thousand USD | 0.0% |
| 2003 FY | 225 Thousand USD | 100.79% |
| 2002 FY | -28.34 Million USD | -163.8% |
| 2001 FY | -10.74 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -10577.965% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2090.261% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -8672.69% |
| CytoDyn Inc. | -18.05 Million USD | 16.68% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 74.494% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -2081498.207% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -728.378% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -198.266% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -50133.707% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -8190.492% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | -55.024% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 72.894% |
| SQZ Biotechnologies Company | -75.82 Million USD | 80.157% |
| Resverlogix Corp. | -12.74 Million USD | -18.017% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3762.207% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 254.437% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -512.793% |
| Mesoblast Limited | -84.14 Million USD | 82.119% |
| GB Sciences, Inc. | -1.42 Million USD | -959.198% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2090.261% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 15.695% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -341.882% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -126.323% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -374.896% |
| ContraFect Corporation | -56.88 Million USD | 73.552% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -446.96% |
| BioStem Technologies, Inc. | -7.77 Million USD | -93.419% |
| LadRx Corporation | -3.82 Million USD | -293.501% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 5.191% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1244.593% |
| CSL Limited | 3.7 Billion USD | 100.406% |
| Biomind Labs Inc. | -1 Million USD | -1390.289% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1515.452% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 118.382% |
| Nascent Biotech, Inc. | -2.22 Million USD | -574.745% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 79.04% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 406.136% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 525.028% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -879.526% |
| Marizyme, Inc. | -34.08 Million USD | 55.859% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -80.192% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2564.315% |
| Zenith Capital Corp. | -8.94 Million USD | -68.243% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -427.836% |
| Halberd Corporation | -75.05 Thousand USD | -19947.968% |
| Genus plc | 6.4 Million USD | 335.094% |
| Pharming Group N.V. | -4.87 Million USD | -208.348% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -657.421% |
| IMV Inc. | -38.67 Million USD | 61.093% |
| SYBLEU INC | -149.18 Thousand USD | -9985.802% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1341.188% |
| Enzolytics Inc. | -2.14 Million USD | -600.205% |
| argenx SE | -425.04 Million USD | 96.46% |
| AVAX Technologies, Inc. | 6.69 Million USD | 324.806% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -973.188% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1026.677% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -301.61% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -59677.513% |
| Cell Source, Inc. | -4.32 Million USD | -247.857% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3014.714% |
| Q BioMed Inc. | -3.44 Million USD | -336.671% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -254.991% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1097.93% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -472.631% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -230.338% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 72.63% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -418.604% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2165.964% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1428.983% |
| Skye Bioscience, Inc. | -13.67 Million USD | -10.051% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -707.029% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -650.515% |
| ONE Bio Corp. | 13.68 Million USD | 209.973% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -678.533% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1237.534% |
| Agentix Corp. | -1.37 Million USD | -996.842% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -415.372% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -852.667% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -86267.028% |
| Kadimastem Ltd | -3.04 Million USD | -394.894% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -5648.76% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3521.362% |
| NovAccess Global Inc. | -2.46 Million USD | -509.95% |
| Itoco Inc. | -919.14 Thousand USD | -1536.965% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -6736.667% |
| Qrons Inc. | -643.67 Thousand USD | -2237.508% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2613.191% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.381% |
| International Stem Cell Corporation | -663 Thousand USD | -2169.382% |
| Bioxytran, Inc. | -3.82 Million USD | -293.859% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -28482.827% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -73872.468% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 58.512% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -829.913% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1944.752% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -383.639% |
| Neutra Corp. | -229.48 Thousand USD | -6456.391% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 14.214% |
| PureTech Health plc | -146.19 Million USD | 89.709% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 29.99% |
| IXICO plc | -1.43 Million USD | -947.042% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -58.529% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 87.648% |
| CSL Limited | 3.81 Billion USD | 100.395% |
| Cellectis S.A. | -108.85 Million USD | 86.178% |